Evidence map›Paper›PMID 42368575›Full record

ArticleActa pharmaceutica Sinica. B2026

Structural characterization of emulsion-type cataplasms with cross-linked networks and systematic establishment of structural parameters.

Peng Yan, Ying Zhou, Hailong Zhang, Jinsong Ding

Abstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Peng YanXiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
Ying ZhouXiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
Hailong ZhangChangsha Jingyi Pharmaceutical Technology Co., Ltd., Changsha 410205, China.
Jinsong DingXiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compared with conventional cataplasms, those incorporating a cross-linked network structure significantly enhance their mechanical strength and cohesion, endowing them with good formability and adhesion properties, solving problems such as cold flow and slippage, thereby greatly increasing the convenience of use. However, systematic studies investigating the structural profiling of cross-linked networks in cataplasms remain scarce, limiting a comprehensive understanding of their functional significance. Therefore, we developed a systematic methodology to characterize emulsion-type cataplasms (as a model formulation) with cross-linked network structures, classifying their key structural parameters into four levels. The primary structures defined formability and adhesion, ensuring intact and durable skin adhesion. The secondary structure was intermediates formed by the drug and oily components. The tertiary structure was a dynamic structure, evaluating the quality changes of cataplasms during processes such as crosslinking and storage. The quaternary structure was a molecular structure, representing the mechanism by which the cross-linked network structure was formed. The factors influencing structural parameters and the laws between the intrinsic structures were investigated. Furthermore, we established threshold values for the primary structures, indicating when cataplasms possess optimal formability. This study offers new insights for cataplasm design and provides valuable references for industrial development.

Indexed as

AdhesionCharacterizationCross-linked networksEmulsion-type cataplasmsFormabilityFour levelsIndustrial developmentStructural parameters

Identifiers

PMID42368575
PMCPMC13304779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.